Susie Lew, MD
Nephrology · Washington, DCNPI 1255423752
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by AstraZeneca at 32.8% of the total. Reporting peaked in 2024 at $1,057 and has fallen 76.4% since, to $250 in 2025.
Across 19 payments — averaging $143.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$892
- Novo Nordisk$675
- Otsuka America Pharmaceutical, Inc.$211
- Amgen$196
- Astrazeneca UK Limited$135
- Travere Therapeutics, Inc.$129
- plus $483 from 5 others
What the payments were for
- Consulting fees$1,45353%
- Food & beverage$1,19644%
- Education$723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $892 |
| Novo Nordisk | 1 | $675 |
| Otsuka America Pharmaceutical, Inc. | 3 | $211 |
| Amgen(2 entities) | 3 | $196 |
| Astrazeneca UK Limited | 1 | $135 |
| Travere Therapeutics, Inc. | 1 | $129 |
| Akebia Therapeutics Inc | 1 | $125 |
| Ardelyx, Inc. | 1 | $103 |
| Medtronic | 1 | $101 |
| Aurinia Pharma U.S., Inc. | 1 | $82 |
| Fresenius USA Marketing, Inc. | 3 | $72 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,721 in reported general payments places this provider in the 70th percentile of 62 nephrology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 11 | $3,790 |
| Labetalol Hcl | 35 | $1,075 |
| Gentamicin Sulfate | 25 | $803 |
| Bumetanide | 11 | $735 |
| Nifedipine ErNifedipine | 40 | $734 |
| Calcium Acetate | 16 | $585 |
| Amlodipine Besylate | 31 | $553 |
| Hydralazine Hcl | 51 | $266 |
| Losartan Potassium | 40 | $204 |
| Lisinopril | 21 | $167 |
| Allopurinol | 13 | $142 |
| Furosemide | 28 | $131 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 11 | $107 |
| Atorvastatin Calcium | 12 | $67 |
| Amoxicillin | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Washington
- Ashte CollinsWashington$1M
- Bruce LeslieWashington$217K
- Janani RangaswamiWashington$152K
- Robert RubinWashington$119K
- Ehsan Nobakht HaghighiWashington$50K
- Christopher WilcoxWashington$41K
- Michael LipkowitzWashington$21K
- Dominic RajWashington$19K
- Cosette JamiesonWashington$13K
- Elwin BustosWashington$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.